Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt

Coronavirus: early-phase trial registry

6 of 21 indexed Coronavirus trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #797 of 28,707 conditions by registered trial count.

21 US clinical trials · 6 currently recruiting · #797 of 28,707 conditions by registered trial count

Coronavirus: 21 US clinical trials tracked, 6 recruiting.

Coronavirus is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 2 of these trials.

Enrollment posture brief

Registry condition coronavirus

OPEN 6 | RECR 29% | LATE 2 | EARLY 7 | RANK #797 | SPON 2

Nearest open-share peer: Acne Scars (29% recruiting · 7 trials)

Anal Cancer42.9%Coronavirus (this)29%Allergic Conjunctivitis14.3%Attention Deficit Disorder W4.8%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Coronavirus

Coronavirus lists 6 open slots (29% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Coronavirus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Coronavirus is recruiting below its size-band peers.

    6 of 21 indexed trials (28.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Coronavirus trials is spread across many organizations.

    Massachusetts General Hospital accounts for 2 of 21 trials (9.5%). 20 distinct sponsors appear on at least one study for this condition label.

  3. Typical Coronavirus enrolment sits around 240 participants.

    Median target enrolment is 240 among the 21 trials that report a genuine target (sentinel values excluded). 3 of those (14.3%) plan for fewer than 100 participants.

  4. Coronavirus splits between interventional and observational designs.

    13 interventional and 8 observational studies make up this index (61.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 25Phase 32

Open and recent trials

21 total, page 1 of 1

RECRUITING 1,500 participants

Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses

BioFire Defense

NCT07221097

RECRUITING 1,000 participants

ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers

Columbia University

NCT04367857

RECRUITING 1,000 participants

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04772170

RECRUITING 250 participants

A Study to Explore the Role of Gut Flora in COVID-19 Infection

ProgenaBiome

NCT04359836

RECRUITING NA 240 participants

Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study

KidSIM Simulation Program

NCT05868239

RECRUITING Phase 3 240 participants

Convalescent Plasma Collection and Treatment in Pediatrics and Adults

West Virginia University

NCT04376034

ACTIVE NOT RECRUITING 201 participants

COVID-19 Biorepository

University of Kansas Medical Center

NCT04568148

COMPLETED NA 14,267 participants

COVID-19 Health Messaging to Underserved Communities

National Bureau of Economic Research

NCT04371419

COMPLETED 6,894 participants

Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic

Pregistry

NCT04385238

COMPLETED Phase 3 479 participants

Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease

Massachusetts General Hospital

NCT04332991

COMPLETED 461 participants

Evaluation of Antibody Tests for COVID-19

Washington University School of Medicine

NCT04360954

COMPLETED Phase 2 368 participants

University of Utah COVID-19 Hydrochloroquine Trial

University of Utah

NCT04342169

COMPLETED NA 290 participants

Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning

Dascena

NCT04423991

COMPLETED Phase 2 200 participants

Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19

Massachusetts General Hospital

NCT04306393

COMPLETED Phase 2 180 participants

Convalescent Plasma to Stem Coronavirus (CSSC-001)

Johns Hopkins University

NCT04323800

COMPLETED Phase 2 159 participants

A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection

TriHealth

NCT04392232

COMPLETED NA 129 participants

NOWDx Test for the Detection of Antibodies to COVID-19

NOWDiagnostics

NCT04690413

COMPLETED 125 participants

Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19

University of Pennsylvania

NCT04379544

COMPLETED Phase 1 72 participants

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

Apellis Pharmaceuticals

NCT04402060

COMPLETED Phase 2 48 participants

Convalescent Plasma in the Treatment of COVID 19

Trinity Health Of New England

NCT04343261

COMPLETED Phase 1 3 participants

Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19

Memorial Sloan Kettering Cancer Center

NCT04824443

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 2

Named interventions

Most-linked intervention names on Coronavirus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Hydroxychloroquine Drug
2 trials
Observation only Other
1 trials
APL-9 Drug
1 trials
Convalescent Plasma Biological
1 trials
Messaging Behavioral
1 trials
NOWDx COVID-19 Test Device
1 trials
SARS-CoV-2 non-immune Plasma Biological
1 trials
Anti- SARS-CoV-2 Plasma Biological
1 trials

US sites by state

Facility locations filed on Coronavirus trials. A trial with sites in several states counts in each.

California 8 trials
Florida 5 trials
New York 4 trials
Massachusetts 4 trials
Michigan 3 trials
Louisiana 3 trials
Arizona 3 trials
Texas 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Coronavirus page

21 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Coronavirus condition card totals 21 registered trials; most-linked intervention Hydroxychloroquine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.